<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2022.875134</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: A cross-sectional study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Anran</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1639439/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Yapeng</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1673971/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname> <given-names>Lue</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Kai</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1679988/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Shaohua</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zong</surname> <given-names>Ce</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname> <given-names>Bo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1025104/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gao</surname> <given-names>Yuan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1437364/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Yusheng</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tian</surname> <given-names>Chuansheng</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xing</surname> <given-names>Yurong</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xu</surname> <given-names>Yuming</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/400478/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname> <given-names>Longde</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou</institution>, <addr-line>Henan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Chinese Preventive Medicine Association</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Physical Examination Center, The First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>The General Office of Stroke Prevention Project Committee, National Health Commission of the People&#x00027;s Republic of China</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: John Zhang, Loma Linda University, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Danhong Wu, Fudan University, China; Carlos Garcia Santos-Gallego, Mount Sinai Hospital, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Yuming Xu <email>xuyuming&#x00040;zzu.edu.cn</email></corresp>
<corresp id="c002">Longde Wang <email>longed_wang&#x00040;yeah.net</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Neurological Biomarkers, a section of the journal Frontiers in Neurology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>875134</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>08</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Wang, Li, Zhou, Liu, Li, Zong, Song, Gao, Li, Tian, Xing, Xu and Wang.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Li, Zhou, Liu, Li, Zong, Song, Gao, Li, Tian, Xing, Xu and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license></permissions>
<abstract>
<sec>
<title>Background</title>
<p>Carotid atherosclerosis, especially the rupture of unstable plaques, plays an important role in the development of stroke. A novel lipid ratio, the non-high-density lipoprotein cholesterol (non-HDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio, contains both atherogenic and anti-atherogenic particle information, and has been shown to be associated with carotid atherosclerosis. However, there is no data on evaluating the association between non-HDL-C/HDL-C ratio and carotid plaque stability.</p></sec>
<sec>
<title>Methods</title>
<p>This study was carried out on 27,436 urban workers aged 20 years or older who participated in a comprehensive health screening between January 2016 and December 2017. Carotid plaque stability was assessed using ultrasonography. Multinomial logistic regression models were used to explore the relationship between the non-HDL-C/HDL-C ratio and carotid plaque stability by odds ratios (<italic>ORs</italic>) and 95% confidence intervals (<italic>CIs</italic>). Subgroup and sensitivity analyses were performed to verify the robustness of the results.</p></sec>
<sec>
<title>Results</title>
<p>Carotid plaque was detected in 7,161 (26.1%) participants, with stable and unstable plaque accounting for 3,277 (11.9%) and 3,884 (14.2%), respectively. The prevalence of stable carotid plaque substantially increased with increasing non-HDL-C/HDL-C ratio quartile levels (<italic>p</italic> for trend &#x0003C; 0.001) and with a similar association for unstable carotid plaque (<italic>p</italic> for trend &#x0003C; 0.001). The mean non-HDL-C/HDL-C ratios (mean &#x000B1; <italic>SD</italic>) of non-carotid plaque (2.9 &#x000B1; 1.1), stable carotid plaque (3.2 &#x000B1; 1.2), and unstable carotid plaque (3.4 &#x000B1; 1.4) gradually increased (<italic>p</italic> &#x0003C; 0.001). In multinomial logistic regression, <italic>ORs</italic> (95% <italic>CIs</italic>) for the highest vs. lowest quartile of the non-HDL-C/HDL-C ratio were 1.70 (1.48&#x02013;1.95) between stable carotid plaques and no carotid plaque, 2.34 (2.06&#x02013;2.67) between unstable carotid plaques and no carotid plaque, and 1.38 (1.18&#x02013;1.61) between unstable carotid plaques and stable carotid plaque, after adjusting for common cardiovascular risk factors. The results of subgroup analysis and sensitivity analysis were similar.</p></sec>
<sec>
<title>Conclusion</title>
<p>Our findings suggested that the non-HDL-C/HDL-C ratio was significantly associated with carotid plaque stability and might be a useful indicator for the early identification of high-risk carotid plaque.</p></sec></abstract>
<kwd-group>
<kwd>lipid ratio</kwd>
<kwd>non-HDL-C/HDL-C</kwd>
<kwd>carotid plaque</kwd>
<kwd>stability</kwd>
<kwd>cross-sectional study</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="41"/>
<page-count count="09"/>
<word-count count="5808"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Stroke is a leading cause of death and disability worldwide (<xref ref-type="bibr" rid="B1">1</xref>). Carotid plaque stability plays a fundamental role in the development of ischemic stroke (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Rupture of unstable carotid plaque can lead to thrombosis, resulting in cerebrovascular occlusion and infarction. Approximately, 18&#x02013;25% of ischemic stroke thromboembolisms originate from ruptured carotid plaques (<xref ref-type="bibr" rid="B4">4</xref>), and carotid plaque is also an important cause of cryptogenic stroke (<xref ref-type="bibr" rid="B5">5</xref>). However, carotid ultrasound screening in the general population is not recommended in the current guideline (<xref ref-type="bibr" rid="B6">6</xref>). Therefore, early identification of carotid plaque stability could help discover people at high risk of stroke, who might benefit from early pharmacological or surgical intervention.</p>
<p>It is well-known that high-density lipoprotein cholesterol (HDL-C) and non-HDL cholesterol (non-HDL-C) are associated with atherosclerosis (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>). Non-HDL-C is considered to be a key factor underlying the process contributing to cardiovascular disease and atherosclerosis (<xref ref-type="bibr" rid="B10">10</xref>). The National Lipid Association has identified non-HDL-C as a primary therapeutic target (<xref ref-type="bibr" rid="B11">11</xref>), HDL-C, which is composed of the smallest and densest lipoprotein particles, inhibits atherosclerosis (<xref ref-type="bibr" rid="B12">12</xref>). HDL-C is negatively associated with cardiovascular (CV) events with each 1 mg/dl increase reducing CV events by 2&#x02013;3% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>), and it exerts cardiovascular protective effects mainly through reverse cholesterol transfer, anti-inflammatory, antioxidant, anti-apoptotic, and vasodilatory effects (<xref ref-type="bibr" rid="B14">14</xref>). A novel lipid ratio, the non-HDL-C/HDL-C ratio, contains both atherogenic and anti-atherogenic particles information, and has been shown to be associated with a variety of dyslipidemia-related diseases such as diabetes mellitus (<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>), liver disease (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>), metabolic syndrome (<xref ref-type="bibr" rid="B20">20</xref>), and previous studies also demonstrated that the non-HDL-C/HDL-C ratio was associated with carotid atherosclerosis (<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>). In addition, the Atherosclerosis Risk in Communities (ARIC) study even found an independent association between non-HDL-C/HDL-C ratio and carotid plaque lipid core (<xref ref-type="bibr" rid="B24">24</xref>). The thicker the lipid core, the more likely it is to cause expansion of the necrotic core of the plaque, resulting in plaque rupture (<xref ref-type="bibr" rid="B25">25</xref>). Moreover, recently studies showed that the non-HDL-C/HDL-C ratio might be a better predictor of cardiovascular events than traditional lipid indices (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). However, to date, there is no data on evaluating the association between non-HDL-C/HDL-C ratio and carotid plaque stability.</p>
<p>Therefore, we performed this study to clarify whether non-HDL-C/HDL-C ratio is significantly associated with carotid plaque stability.</p></sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec>
<title>Participants</title>
<p>The study population consisted of 28,537 Chinese adults who participated in a health examination in stroke screening sites of the First Affiliated Hospital of Zhengzhou University from January 2016 to December 2017. The exclusion criteria of this study were: subjects with any history of malignancy, infectious diseases, acute inflammation, liver disease, or renal disease. We also excluded subjects with missing data on TC or fasting blood glucose (FBG). After applying our exclusion criteria, a total of 27,436 participants were enrolled in this study.</p>
</sec>
<sec>
<title>Data collection</title>
<p>We collected individual sociodemographic information (e.g., sex, age, and education), history of chronic diseases (e.g., diabetes, dyslipidemia, hypertension, coronary heart disease, and stroke), and lifestyle factors (e.g., smoking, drinking, vegetable and fruit consumption, physical activity, etc.) <italic>via</italic> a standard questionnaire by trained interviewers. Definition of history of stroke and coronary artery disease: previously diagnosed by a medical specialist or provided imaging data to support the diagnosis. Smoking, defined as smoking 1 cigarette per day for more than 1 year. Drinking, defined as alcoholic drink of at least &#x02265;45 g each time per day during the last year. Vegetable consumption and Fruit consumption were divided into two groups (&#x02265;5 days/week and &#x0003C;5 days/week) using a standard consumption of 200 g per day. Physical activity, defined as regular exercise for at least 30 min per time in no less than 3 times per week. We measured weight, height, and resting blood pressure such as systolic blood pressure (SBP) and diastolic blood pressure (DBP). Obesity was defined as BMI &#x02265; 28 kg/m<sup>2</sup>.</p>
<p>In addition, overnight fasting blood samples were obtained from all subjects. Fasting blood glucose was measured using the glucose oxidase method. Lipid levels including total cholesterol (TC), triglyceride (TG), HDL-C, and low-density lipoprotein cholesterol (LDL-C) were measured using Olympus Au5400 automated biochemistry analyzer (First Chemical Co, Ltd, Japan). Hypertension was defined as SBP and/or DBP &#x02265; 140/90 mmHg, or the usage of antihypertensive medications. Dyslipidemia was defined as TG &#x02265; 2.26 mmol/L, TC &#x02265; 6.22 mmol/L, HDL-C &#x0003C; 1.04 mmol/L, LDL-C &#x02265; 4.14 mmol/L, self-reported history, or taking lipid-lowering drugs. Diabetes mellitus (DM) was defined as self-reported history, FPG &#x02265; 7.0 mmol/L, or taking antidiabetic agents.</p>
</sec>
<sec>
<title>Assessment of carotid plaque stability</title>
<p>Ultrasound technologists evaluated carotid plaques by qualified sonographers using the iU22 (Philips Healthcare), HA500 (Hitachi Healthcare), and DC-8 (Mindray), ultrasound system with 5&#x02013;10 MHz transmission frequency. Two qualified sonographers measured each participant separately; discrepancies in measurement data were resolved by consensus. We examined plaques of bilateral common carotid artery, internal carotid artery, external carotid artery, and bulb. Carotid plaque was defined as a focal structure encroaching into the arterial lumen by at least 0.5 mm or 50% of the surrounding CIMT value, or CIMT &#x0003E; 1.5 mm (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Stable carotid plaques had a high level of homogeneous echogenicity and homogeneous texture with a regular smooth morphology. Unstable carotid plaques had an incomplete fibrous cap or ulceration with low level or heterogeneous echogenicity (<xref ref-type="bibr" rid="B30">30</xref>).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The population was divided into four groups based on the quartiles of the non-HDL-C/HDL-C ratio. Categorical variables were presented as frequency (%), which was compared using chi-square analysis. Continuous variables were described as the median with an interquartile range owing to the skewed distribution, which were compared by variance (ANOVA) or Mann&#x02013;Whitney <italic>U</italic>-tests for continuous variables.</p>
<p>When participants were divided into 3 groups according to carotid plaque stability (non-carotid plaque, stable carotid plaque, and unstable carotid plaque), multinomial logistic regression models were used to explore the relationship between the non-HDL-C/HDL-C ratio and carotid plaque stability. To adjust for potential confounders, two models were developed: Model 1, adjusted for age, sex, education, smoking status, drinking status, vegetable consumption, fruit consumption, physical activity, BMI &#x02265; 28 kg/m<sup>2</sup> (yes or no), stroke, coronary heart disease, hypertension, antihypertensive agents, diabetes mellitus, antidiabetic agents, lipid-lowering agents; Model 2, further adjusted for TG and FBG. The results were presented as odds ratios (<italic>ORs</italic>) and 95% confidence intervals (<italic>CIs</italic>). To verify the robustness of the relationship between non-HDL-C/HDL-C ratio and carotid plaque stability, analyses were carried out for different subgroups. In view of the effect of lipid-lowering agents on non-HDL-C/HDL-C ratio and carotid plaque stability, sensitivity analysis was performed after excluding people taking lipid-lowering agents.</p>
<p>All analyses above were conducted using R software (version 3.6.3). A two-sided <italic>p</italic> &#x0003C; 0.05 was considered statistically significant.</p></sec></sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Baseline characteristics</title>
<p>A total of 27,436 participants were recruited, 12,866 (46.9%) of them were male. The median (IQR) age of overall participants was 48 (41&#x02013;55) years, and the median non-HDL-C/HDL-C ratio was 2.82 (<italic>IQR</italic>: 2.16&#x02013;3.60). Compared with participants in the lowest quartile of non-HDL-C/HDL-C ratio, those with higher non-HDL-C/HDL-C ratio were more likely to be older and male; to be smoking, drinking, vegetable, and fruit consumption, active physical activity, obesity; to have a higher prevalence of hypertension, diabetes, and dyslipidemia; to have higher use of antidiabetic, antihypertensive, and lipid-lowering agents use, to have a higher level of SBP, DBP, FBG, TC, TG, LDL-C, and non-HDL level, while more likely to have a lower level of HDL-C. The characteristics of participants according to quartiles of the non-HDL-C/HDL-C ratio are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Baseline characteristics of the study participants.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Characteristics</bold></th>
<th valign="top" align="center"><bold>Overall</bold></th>
<th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;"><bold>Quartiles of the Non-HDL-C/HDL-C ratio</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-value<xref ref-type="table-fn" rid="TN1"><sup>&#x02020;</sup></xref></bold></th>
</tr>
<tr>
<th/>
<th/>
<th valign="top" align="center"><bold>Q1 (&#x0003C;2.16)</bold></th>
<th valign="top" align="center"><bold>Q2 (2.16&#x02013;2.82)</bold></th>
<th valign="top" align="center"><bold>Q3 (2.82&#x02013;3.60)</bold></th>
<th valign="top" align="center"><bold>Q4 (&#x0003E;3.60)</bold></th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">No. of patients</td>
<td valign="top" align="center">27,436</td>
<td valign="top" align="center">6,858</td>
<td valign="top" align="center">6,857</td>
<td valign="top" align="center">6,863</td>
<td valign="top" align="center">6,858</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Age, years</td>
<td valign="top" align="center">48.0 (41.0&#x02013;55.0)</td>
<td valign="top" align="center">44.0 (39.0&#x02013;52.0)</td>
<td valign="top" align="center">48.0 (41.0&#x02013;55.0)</td>
<td valign="top" align="center">49.0 (43.0&#x02013;56.0)</td>
<td valign="top" align="center">50.0 (44.0&#x02013;57.0)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Male, sex</td>
<td valign="top" align="center">12,866 (46.9)</td>
<td valign="top" align="center">1,812 (26.4)</td>
<td valign="top" align="center">2,785 (40.6)</td>
<td valign="top" align="center">3,641 (53.1)</td>
<td valign="top" align="center">4,628 (67.5)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">High school or above, <italic>n</italic> (%)</td>
<td valign="top" align="center">17,032 (62.1)</td>
<td valign="top" align="center">4,819 (70.3)</td>
<td valign="top" align="center">4,367(63.7)</td>
<td valign="top" align="center">4,046 (59.0)</td>
<td valign="top" align="center">3,800 (55.4)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Smoking, <italic>n</italic> (%)</td>
<td valign="top" align="center">6,548 (23.9)</td>
<td valign="top" align="center">803 (11.7)</td>
<td valign="top" align="center">1,335 (19.5)</td>
<td valign="top" align="center">1,785 (26.0)</td>
<td valign="top" align="center">2,625 (38.3)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Drinking, <italic>n</italic> (%)</td>
<td valign="top" align="center">5,401 (19.7)</td>
<td valign="top" align="center">690 (10.1)</td>
<td valign="top" align="center">1,165 (17.0)</td>
<td valign="top" align="center">1,547 (22.5)</td>
<td valign="top" align="center">1,999 (29.1)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Vegetable (&#x0003C;5d/w), <italic>n</italic> (%)</td>
<td valign="top" align="center">12,940 (47.2)</td>
<td valign="top" align="center">2,692 (43.3)</td>
<td valign="top" align="center">2,878 (46.3)</td>
<td valign="top" align="center">2,982 (47.9)</td>
<td valign="top" align="center">3,060 (49.2)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Fruit (&#x0003C;5d/w), <italic>n</italic> (%)</td>
<td valign="top" align="center">22,734 (82.9)</td>
<td valign="top" align="center">5,555 (81.0)</td>
<td valign="top" align="center">5,586 (81.5)</td>
<td valign="top" align="center">5,747 (83.7)</td>
<td valign="top" align="center">5,844 (85.2)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Active physical activity, n (%)</td>
<td valign="top" align="center">19,798 (72.2)</td>
<td valign="top" align="center">4,805 (70.1)</td>
<td valign="top" align="center">5,046 (73.6)</td>
<td valign="top" align="center">5,005 (72.9)</td>
<td valign="top" align="center">4,942 (72.1)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">BMI &#x02265; 28 (kg/m<sup>2</sup>)</td>
<td valign="top" align="center">4,595 (16.7)</td>
<td valign="top" align="center">457 (6.7)</td>
<td valign="top" align="center">869 (12.7)</td>
<td valign="top" align="center">1,301 (19.0)</td>
<td valign="top" align="center">1,968 (28.7)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Hypertension, <italic>n</italic> (%)</td>
<td valign="top" align="center">11,236 (41.0)</td>
<td valign="top" align="center">1,992 (29.0)</td>
<td valign="top" align="center">2,510 (36.6)</td>
<td valign="top" align="center">3,090 (45.0)</td>
<td valign="top" align="center">3,644 (53.1)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Diabetes, <italic>n</italic> (%)</td>
<td valign="top" align="center">2,914 (10.6)</td>
<td valign="top" align="center">389 (5.7)</td>
<td valign="top" align="center">553 (8.1)</td>
<td valign="top" align="center">746 (10.9)</td>
<td valign="top" align="center">1,226 (17.9)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Dyslipidemia, <italic>n</italic> (%)</td>
<td valign="top" align="center">10,403 (37.9)</td>
<td valign="top" align="center">370 (5.4)</td>
<td valign="top" align="center">1,226 (17.9)</td>
<td valign="top" align="center">2,997 (43.7)</td>
<td valign="top" align="center">5,810 (84.7)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Antihypertensive agents, <italic>n</italic> (%)</td>
<td valign="top" align="center">3,580 (13.0)</td>
<td valign="top" align="center">615 (9.0)</td>
<td valign="top" align="center">790 (11.5)</td>
<td valign="top" align="center">973 (14.2)</td>
<td valign="top" align="center">1,202 (17.5)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Antidiabetic agents, <italic>n</italic> (%)</td>
<td valign="top" align="center">1,305 (4.8)</td>
<td valign="top" align="center">191 (2.8)</td>
<td valign="top" align="center">273 (4.0)</td>
<td valign="top" align="center">348 (5.1)</td>
<td valign="top" align="center">493 (7.2)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Lipid-lowering agents, <italic>n</italic> (%)</td>
<td valign="top" align="center">731 (2.7)</td>
<td valign="top" align="center">110 (1.6)</td>
<td valign="top" align="center">162 (2.4)</td>
<td valign="top" align="center">165 (2.4)</td>
<td valign="top" align="center">294 (4.3)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Stroke, <italic>n</italic> (%)</td>
<td valign="top" align="center">487 (1.8)</td>
<td valign="top" align="center">129 (1.9)</td>
<td valign="top" align="center">108 (1.6)</td>
<td valign="top" align="center">123 (1.8)</td>
<td valign="top" align="center">127 (1.9)</td>
<td valign="top" align="center">0.520</td>
</tr>
<tr>
<td valign="top" align="left">Coronary heart disease, <italic>n</italic> (%)</td>
<td valign="top" align="center">617 (2.2)</td>
<td valign="top" align="center">151 (2.2)</td>
<td valign="top" align="center">146 (2.1)</td>
<td valign="top" align="center">144 (2.1)</td>
<td valign="top" align="center">176 (2.6)</td>
<td valign="top" align="center">0.224</td>
</tr>
<tr>
<td valign="top" align="left">Carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No carotid plaque, <italic>n</italic> (%)</td>
<td valign="top" align="center">20,275 (73.9)</td>
<td valign="top" align="center">5,768 (84.1)</td>
<td valign="top" align="center">5,238 (76.4)</td>
<td valign="top" align="center">4,936 (71.9)</td>
<td valign="top" align="center">4,333 (63.2)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Stable carotid plaque, <italic>n</italic> (%)</td>
<td valign="top" align="center">3,277 (11.9)</td>
<td valign="top" align="center">564 (8.2)</td>
<td valign="top" align="center">748 (10.9)</td>
<td valign="top" align="center">869 (12.7)</td>
<td valign="top" align="center">1,096 (16.0)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Unstable carotid plaque, <italic>n</italic> (%)</td>
<td valign="top" align="center">3,884 (14.2)</td>
<td valign="top" align="center">526 (7.7)</td>
<td valign="top" align="center">871 (12.7)</td>
<td valign="top" align="center">1,058 (15.4)</td>
<td valign="top" align="center">1,429 (20.8)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">DBP, mm Hg</td>
<td valign="top" align="center">81.0 (73.0&#x02013;90.0)</td>
<td valign="top" align="center">77.0 (70.0&#x02013;85.0)</td>
<td valign="top" align="center">80.0 (72.0&#x02013;89.0)</td>
<td valign="top" align="center">83.0 (75.0&#x02013;91.0)</td>
<td valign="top" align="center">85.0 (77.0&#x02013;94.0)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Fasting blood glucose, mmol/L</td>
<td valign="top" align="center">5.20 (4.80&#x02013;5.70)</td>
<td valign="top" align="center">5.00 (4.70&#x02013;5.40)</td>
<td valign="top" align="center">5.10 (4.75&#x02013;5.60)</td>
<td valign="top" align="center">5.20 (4.80&#x02013;5.70)</td>
<td valign="top" align="center">5.40 (4.90&#x02013;6.10)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Total cholesterol, mmol/L</td>
<td valign="top" align="center">4.62 (4.07&#x02013;5.24)</td>
<td valign="top" align="center">4.06 (3.62&#x02013;4.52)</td>
<td valign="top" align="center">4.46 (4.00&#x02013;4.96)</td>
<td valign="top" align="center">4.76 (4.29&#x02013;5.29)</td>
<td valign="top" align="center">5.27 (4.74&#x02013;5.88)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Triglyceride, mmol/L</td>
<td valign="top" align="center">1.26 (0.89&#x02013;1.86)</td>
<td valign="top" align="center">0.82 (0.66&#x02013;1.04)</td>
<td valign="top" align="center">1.10 (0.87&#x02013;1.43)</td>
<td valign="top" align="center">1.43 (1.11&#x02013;1.90)</td>
<td valign="top" align="center">2.11 (1.58&#x02013;2.96)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">HDL cholesterol, mmol/L</td>
<td valign="top" align="center">1.20 (1.03&#x02013;1.41)</td>
<td valign="top" align="center">1.48 (1.31&#x02013;1.67)</td>
<td valign="top" align="center">1.28 (1.14&#x02013;1.43)</td>
<td valign="top" align="center">1.14 (1.02&#x02013;1.27)</td>
<td valign="top" align="center">0.98 (0.88&#x02013;1.10)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">LDL cholesterol, mmol/L</td>
<td valign="top" align="center">2.70 (2.21&#x02013;3.23)</td>
<td valign="top" align="center">2.16 (1.84&#x02013;2.51)</td>
<td valign="top" align="center">2.66 (2.28&#x02013;3.03)</td>
<td valign="top" align="center">2.94 (2.51&#x02013;3.38)</td>
<td valign="top" align="center">3.21 (2.66&#x02013;3.76)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Non-HDL cholesterol, (mmol/l)</td>
<td valign="top" align="center">3.38 (2.82&#x02013;4.00)</td>
<td valign="top" align="center">2.57 (2.24&#x02013;2.91)</td>
<td valign="top" align="center">3.18 (2.84&#x02013;3.56)</td>
<td valign="top" align="center">3.61 (3.25&#x02013;4.04)</td>
<td valign="top" align="center">4.28 (3.82&#x02013;4.80)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>BMI, body mass index; Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as frequencies (percentage);</p>
<fn id="TN1">
<label>&#x02020;</label>
<p><italic>P</italic>-values were derived from Mann&#x02013;Whitney <italic>U</italic>-tests for continuous variables, and Chi-square tests for categorical variables.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Non-HDL-C/HDL-C ratio and carotid plaque stability</title>
<p>Carotid plaque was detected in 7,161 (26.1%) respondents, with stable and unstable plaque accounting for 3,277 (11.9%) and 3,884 (14.2%), respectively. As non-HDL-C/HDL-C ratio levels increased from the lowest quartile to the highest quartile, the prevalence was increased from 8.2 to 16% for stable carotid plaque (<italic>p</italic> for trend &#x0003C; 0.001) and from 7.7 to 20.8% for unstable carotid plaque (<italic>p</italic> for trend &#x0003C; 0.001). The mean non-HDL-C/HDL-C ratios of non-carotid plaque (mean &#x000B1; <italic>SD</italic>, 2.9 &#x000B1; 1.1), stable carotid plaque (mean &#x000B1; <italic>SD</italic>, 3.2 &#x000B1; 1.2), and unstable carotid plaque (mean &#x000B1; <italic>SD</italic>, 3.4 &#x000B1; 1.4) increased gradually and this trend was statistically significant (<italic>p</italic> &#x0003C; 0.001; <xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p><bold>(A)</bold> The mean non-HDL-C /HDL-C ratios of non-carotid plaque, stable carotid plaque, and unstable carotid plaque (mean &#x000B1; <italic>SD</italic>) increased gradually and this trend was statistically significant. <bold>(B)</bold> Prevalence of stable carotid plaque stratified by quartile the non-HDL-C/HDL-C ratio. <bold>(C)</bold> Prevalence of unstable carotid plaque stratified by quartile the non-HDL-C/HDL-C ratio. &#x0002A;&#x0002A;&#x0002A;&#x0002A; <italic>p</italic> &#x0003C; 0.001.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-13-875134-g0001.tif"/>
</fig>
<p>In multinomial logistic regression model 1 compared stable carotid plaques with no carotid plaque, the <italic>ORs</italic> (95% <italic>CIs</italic>) for the highest quartile of the non-HDL-C/HDL-C ratios were 1.71 (1.51&#x02013;1.94). For every 1 unit increase in the non-HDL-C/HDL-C ratio, the prevalence of stable carotid plaque increased by 1.17 times. Compared unstable carotid plaques with no carotid plaque, the <italic>ORs</italic> (95% <italic>CIs</italic>) for the highest quartile of the non-HDL-C/HDL-C ratios were 2.21 (1.96&#x02013;2.49). Moreover, for every 1 unit increase in the non-HDL-C/HDL-C ratio, the prevalence of unstable carotid plaque increased by 1.21 times. Compared to unstable carotid plaques with stable carotid plaque, the <italic>ORs</italic> (95% <italic>CIs</italic>) for the highest quartile of the non-HDL-C/HDL-C ratios were 1.29 (1.12&#x02013;1.50). Moreover, for every 1 unit increase in the non-HDL-C/HDL-C ratio, the prevalence of unstable carotid plaque increased by 1.04 times.</p>
<p>Further adjustment for TG and FBG in model 2 did not change the association between the non-HDL-C/HDL-C ratio and carotid plaque stability. The corresponding <italic>ORs</italic> (95% <italic>CIs</italic>) for the highest vs. lowest quartile of the non-HDL-C/HDL-C ratio were 1.70 (1.48&#x02013;1.95) between stable carotid plaques and no carotid plaque, 2.34 (2.06&#x02013;2.67) between unstable carotid plaques and no carotid plaque, and 1.38 (1.18&#x02013;1.61) between unstable carotid plaques and stable carotid plaque (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Multinomial logistic odds ratios (<italic>ORs</italic>) (95% <italic>CI</italic>) of the association of the non-HDL-C/HDL-C ratio with carotid stability.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Outcomes</bold></th>
<th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;"><bold>Quartiles of the Non-HDL-C/HDL-C ratio</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-trend</bold></th>
<th valign="top" align="center"><bold>Per 1</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="left"><bold>Q1 (&#x0003C;2.16)</bold></th>
<th valign="top" align="center"><bold>Q2 (2.16&#x02013;2.82)</bold></th>
<th valign="top" align="center"><bold>Q3 (2.82&#x02013;3.60)</bold></th>
<th valign="top" align="center"><bold>Q4 (&#x0003E;3.60)</bold></th>
<th/>
<th valign="top" align="center"><bold>unit increase</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Stable vs. non-carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.45 (1.28&#x02013;1.65)</td>
<td valign="top" align="center">1.73 (1.52-1.95)</td>
<td valign="top" align="center">2.37 (2.10-2.67)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.28 (1.24-1.33)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.24 (1.09&#x02013;1.42)</td>
<td valign="top" align="center">1.29 (1.13-1.47)</td>
<td valign="top" align="center">1.71 (1.51-1.94)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.17 (1.13-1.21)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.24 (1.09&#x02013;1.41)</td>
<td valign="top" align="center">1.29 (1.13-1.47)</td>
<td valign="top" align="center">1.70 (1.48-1.95)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.21 (1.15-1.27)</td>
</tr>
<tr>
<td valign="top" align="left">Unstable vs. non-carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.86 (1.64&#x02013;2.12)</td>
<td valign="top" align="center">2.32 (2.04&#x02013;2.63)</td>
<td valign="top" align="center">3.43 (3.04&#x02013;3.88)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.36 (1.32&#x02013;1.41)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.51 (1.33&#x02013;1.71)</td>
<td valign="top" align="center">1.62 (1.44&#x02013;1.83)</td>
<td valign="top" align="center">2.21 (1.96&#x02013;2.49)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.21 (1.18&#x02013;1.25)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.52 (1.35&#x02013;1.73)</td>
<td valign="top" align="center">1.66 (1.47&#x02013;1.88)</td>
<td valign="top" align="center">2.34 (2.06&#x02013;2.67)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.35 (1.30&#x02013;1.41)</td>
</tr>
<tr>
<td valign="top" align="left">Unstable vs. stable carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.29 (1.08&#x02013;1.53)</td>
<td valign="top" align="center">1.34 (1.14&#x02013;1.59)</td>
<td valign="top" align="center">1.45 (1.24&#x02013;1.70)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.06 (1.03&#x02013;1.10)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.22 (1.04&#x02013;1.42)</td>
<td valign="top" align="center">1.26 (1.08&#x02013;1.46)</td>
<td valign="top" align="center">1.29 (1.12&#x02013;1.50)</td>
<td valign="top" align="center">0.002</td>
<td valign="top" align="center">1.04 (1.00&#x02013;1.08)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.23 (1.05&#x02013;1.44)</td>
<td valign="top" align="center">1.29 (1.11&#x02013;1.51)</td>
<td valign="top" align="center">1.38(1.18&#x02013;1.61)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.12 (1.07&#x02013;1.18)</td>
</tr>
</tbody>
</table><table-wrap-foot><p><bold>Model 1:</bold> adjusted for age, sex, education, smoking status, drinking status, vegetable consumption, fruit consumption, physical activity, BMI &#x02265; 28 kg/m<sup>2</sup> (yes or no), stroke, coronary heart disease, hypertension, antihypertensive agents, diabetes mellitus, antidiabetic agents, lipid-lowering agents.</p>
<p><bold>Model 2:</bold> further adjusted for Triglyceride, Fasting blood glucose.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Subgroup analysis and sensitivity analysis</title>
<p>When the non-HDL-C/HDL-C ratio was considered as a continuous variable, subgroup analysis was conducted by stratification according to sex, age, BMI, hypertension, and diabetes. After the full adjustment variables, the association between non-HDL-C/HDL-C ratio and carotid plaque stability remained significant in gender, age, hypertension, and diabetes subgroups. While in a subgroup analysis of BMI &#x02265; 28 (kg/m<sup>2</sup>), there was no statistical significance between unstable carotid plaques and no carotid plaque (<italic>OR</italic> 1.06, 95% <italic>CI</italic> 0.95&#x02013;1.17; <xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Subgroup analysis was conducted by stratification according to sex, age, BMI, hypertension, and diabetes, when the non-HDL-C/HDL-C ratio was considered as a continuous variable. After the fully adjustment, the same variables as Model 3 in <xref ref-type="table" rid="T2">Table 2</xref>, the odds ratios (<italic>ORs</italic>; 95% <italic>CIs</italic>) of the non-HDL-C/HDL-C ratio and carotid stability.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-13-875134-g0002.tif"/>
</fig>
<p>This sensitivity analysis was performed to assess the relationship between non-HDL-C/HDL-C ratio and carotid plaque stability in the subsample without taking lipid-lowering agents. After multivariable adjustment for the risk factors, sensitivity analyses showed similar results (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Sensitivity analysis<xref ref-type="table-fn" rid="TN2"><sup>&#x02020;</sup></xref>.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Outcomes</bold></th>
<th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;"><bold>Quartiles of the Non-HDL-C/HDL-C ratio index</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-trend</bold></th>
<th valign="top" align="center"><bold>Per 1</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>Q1 (&#x0003C;2.16)</bold></th>
<th valign="top" align="center"><bold>Q2 (2.16&#x02013;2.82)</bold></th>
<th valign="top" align="center"><bold>Q3 (2.82&#x02013;3.60)</bold></th>
<th valign="top" align="center"><bold>Q4 (&#x0003E;3.60)</bold></th>
<th/>
<th valign="top" align="center"><bold>Unit increase</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Stable vs. no carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.45 (1.28&#x02013;1.63)</td>
<td valign="top" align="center">1.81 (1.61&#x02013;2.03)</td>
<td valign="top" align="center">2.64 (2.36&#x02013;2.96)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.28 (1.24&#x02013;1.33)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.23 (1.08&#x02013;1.41)</td>
<td valign="top" align="center">1.28 (1.12&#x02013;1.46)</td>
<td valign="top" align="center">1.73 (1.52&#x02013;1.97)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.17 (1.13&#x02013;1.21)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.23 (1.07&#x02013;1.41)</td>
<td valign="top" align="center">1.27 (1.11&#x02013;1.45)</td>
<td valign="top" align="center">1.70 (1.48&#x02013;1.96)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.21 (1.15&#x02013;1.27)</td>
</tr>
<tr>
<td valign="top" align="left">Unstable vs. no carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.82 (1.62&#x02013;2.04)</td>
<td valign="top" align="center">2.40 (2.15&#x02013;2.69)</td>
<td valign="top" align="center">3.61 (3.24&#x02013;4.03)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.36 (1.32&#x02013;1.41)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.50 (1.32&#x02013;1.71)</td>
<td valign="top" align="center">1.64 (1.45&#x02013;1.86)</td>
<td valign="top" align="center">2.18 (1.93&#x02013;2.46)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.21 (1.18&#x02013;1.25)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.51 (1.33&#x02013;1.72)</td>
<td valign="top" align="center">1.67 (1.48&#x02013;1.89)</td>
<td valign="top" align="center">2.28 (2.00&#x02013;2.60)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.35 (1.30&#x02013;1.41)</td>
</tr>
<tr>
<td valign="top" align="left">Unstable vs. stable carotid plaque</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Crude model</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.25 (1.07&#x02013;1.47)</td>
<td valign="top" align="center">1.33 (1.14&#x02013;1.55)</td>
<td valign="top" align="center">1.37 (1.18&#x02013;1.58)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.06 (1.03&#x02013;1.10)</td>
</tr>
<tr>
<td valign="top" align="left">Model 1</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.22 (1.04&#x02013;1.43)</td>
<td valign="top" align="center">1.29 (1.10&#x02013;1.50)</td>
<td valign="top" align="center">1.26 (1.08&#x02013;1.47)</td>
<td valign="top" align="center">0.002</td>
<td valign="top" align="center">1.04 (1.00&#x02013;1.08)</td>
</tr>
<tr>
<td valign="top" align="left">Model 2</td>
<td valign="top" align="left">Reference</td>
<td valign="top" align="center">1.23 (1.05&#x02013;1.45)</td>
<td valign="top" align="center">1.32 (1.13&#x02013;1.54)</td>
<td valign="top" align="center">1.34 (1.14&#x02013;1.58)</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">1.12 (1.07&#x02013;1.18)</td>
</tr>
</tbody>
</table><table-wrap-foot><p>Multinomial logistic <italic>ORs</italic> (95% <italic>CI</italic>) of the association of the non-HDL-C/HDL-C ratio with carotid plaque and its stability.</p>
<p>Model 1: adjusted for age, sex, education, smoking status, drinking status, vegetable consumption, fruit consumption, physical activity, BMI &#x02265; 28 kg/m<sup>2</sup> (yes or no), stroke, coronary heart disease, hypertension, antihypertensive agents, diabetes mellitus, antidiabetic agents, lipid-lowering agents.</p>
<p>Model 2: further adjusted for Triglyceride, Fasting blood glucose.</p>
<fn id="TN2">
<label>&#x02020;</label>
<p>Sensitivity analysis was performed in participants without taking lipid-lowering agents.</p></fn>
</table-wrap-foot>
</table-wrap></sec></sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>This is the first population-based study to explore the relationship between non-HDL-C/HDL-C ratio and carotid plaque stability. We found that the prevalence of both stable and unstable carotid plaque increased significantly with increasing non-HDL-C/HDL-C ratios, independent of other relevant factors. Meanwhile, the mean non-HDL-C /HDL-C ratio gradually increased for non-carotid plaques, stable carotid plaques, and unstable carotid plaques; and this trend was statistically significant. Our findings, for the first time, demonstrated that non-HDL-C /HDL-C ratio was associated with carotid plaque stability in the general population.</p>
<p>Early atherosclerosis occurs mainly in the peripheral vasculature, such as the femoral and carotid arteries (<xref ref-type="bibr" rid="B31">31</xref>). The burden of carotid atherosclerosis has been increasing. A systematic review revealed the global burden of carotid atherosclerotic disease, with 21.1% of people aged 30&#x02013;79 years suffering from carotid plaque in 2020, equivalent to 815.76 million people (<xref ref-type="bibr" rid="B32">32</xref>), and it was known that unstable plaque was an important factor in the development of cardiovascular disease (<xref ref-type="bibr" rid="B33">33</xref>). Moreover, many studies had shown that early preventive treatment and risk factor intervention were beneficial (<xref ref-type="bibr" rid="B34">34</xref>&#x02013;<xref ref-type="bibr" rid="B36">36</xref>). However, carotid ultrasound screening in the general population is not recommended in the current guideline (<xref ref-type="bibr" rid="B6">6</xref>). Therefore, simple and accessible biomarkers for early determination of carotid plaque stability can help improve the understanding of the pathophysiology of cardiovascular disease and identify high-risk patients who may benefit from early intervention.</p>
<p>Our study found a gradual increase in the prevalence of carotid plaque as the non-HDL-C/HDL-C ratio gradually increased. As with our findings, the previous studies had shown that the non-HDL-C/HDL-C ratio was associated with carotid atherosclerosis (<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>). Qin et al. (<xref ref-type="bibr" rid="B21">21</xref>) found that carotid intima-media thickness gradually increased in the quartile of non-HDL-CHDL-C ratio in Chinese individuals of metabolic syndrome (<italic>p</italic> trend &#x0003C; 0.05). A multicenter study (<xref ref-type="bibr" rid="B22">22</xref>) found that postmenopausal women with higher non-HDL-C/HDL-C ratios had a greater chance of developing carotid atherosclerotic plaque (<italic>OR</italic>: 1.30, 95% <italic>CI</italic>: 1.07&#x02013;1.58, <italic>p</italic> = 0.009) when adjusted for other cardiovascular risk factors. Recently, studies found that the non-HDL-C/HDL-C ratio might be a more accurate predictor of cardiovascular disease (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). In addition, an asymptomatic polyvascular abnormalities in Community study (<xref ref-type="bibr" rid="B37">37</xref>) found that the odds of unstable carotid plaques at non-HDL-C levels in the middle and highest trilaterals were 1.02 (95% <italic>CI</italic>, 0.84&#x02013;1.23) and 1.50 (95% <italic>CI</italic>, 1.23&#x02013;1.82), respectively, after adjusting for confounders. Moreover, ARIC (<xref ref-type="bibr" rid="B24">24</xref>) study even found an independent association between non-HDL-C/HDL-C ratio and carotid plaque lipid core. It is well-known that plaque rich in lipid core is unstable and easy to rupture (<xref ref-type="bibr" rid="B25">25</xref>). All the above studies indirectly supported our findings that the non-HDL-C/HDL-C ratio might be associated with carotid plaque stability.</p>
<p>As a clinically easily accessible biomarker, the non-HDL-C/HDL-C ratio collects information on all atherogenic and antiatherogenic lipid particles. Non-high-density lipoprotein cholesterol (non-HDL-C) level is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) from TC. Non-HDL-C consists of LDL-C, very low-density lipoprotein (VLDL-C), intermediate-density lipoprotein (IDL-C), chylomicrons, and their TG-rich lipoprotein remnants, and the protein mainly contains apolipoprotein B, which is a strong indicator of atherogenicity (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Non-HDL-C is considered to be a key factor underlying the process contributing to most cardiovascular diseases (<xref ref-type="bibr" rid="B10">10</xref>). The National Lipid Association has identified non-HDL-C as a primary therapeutic target (<xref ref-type="bibr" rid="B11">11</xref>), and the ESC/EAS guidelines for the management of dyslipidemia also recommended the inclusion of non-HDL in the assessment of cardiovascular disease risk (<xref ref-type="bibr" rid="B39">39</xref>). HDL-C is composed of the smallest and densest lipoprotein particles and mainly contains apolipoprotein A-I (APOA-I), which inhibits the production and mobilization of inflammatory cells and promotes the reversal of cholesterol transport (RCT) to inhibit atherosclerosis (<xref ref-type="bibr" rid="B12">12</xref>). HDL-C is thought to be negatively associated with cardiovascular disease events (<xref ref-type="bibr" rid="B7">7</xref>). The non-HDL-C/HDL-C ratio can reflect the balance between atherogenic and anti-atherogenic lipid particles, which may be the underlying mechanism for its relationship with plaque stability.</p>
<p>There are several limitations in our study. First, this is a cross-sectional study and no conclusions can be drawn on the causal relationship between non-HDL-C/HDL-C ratio and carotid plaque stability. Second, carotid plaque stability is assessed using ultrasound, which is not as accurate as MRI or angiography and cannot be verified with pathological specimens. However, we corrected for bias with a two-person blinded assessment. Third, our study did not collect information on HDL functionality, which is a better predictor of CV risk than HDL-C levels (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>), and it may be useful for high-risk carotid plaque identification. Finally, we did not collect follow-up information, which limited our ability to prospectively study, the impact of baseline non-HDL-C/HDL-C ratio on the evolution of plaque stability and cardiovascular events. Therefore, future prospective cohort studies are clearly needed.</p></sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusions</title>
<p>In conclusion, this study found that the non-HDL-C/HDL-C ratio was associated with carotid plaque stability in the general population. The non-HDL-C/HDL-C ratio was highest in those with unstable carotid plaque, followed by those with stable carotid plaque and lowest in those with no carotid plaque. Our findings suggest that an elevated non-HDL-C/HDL-C ratio is independently associated with carotid plaque and its stability.</p></sec>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p></sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Written informed consent to participate in this study was provided by the patient/participants legal guardian/next of kin.</p></sec>
<sec id="s8">
<title>Author contributions</title>
<p>YMX and LW designed the research. YPL, LZ, YG, KL, SL, CZ, and YRX helped with the acquisition and analysis of the data. AW wrote the article. BS, YG, CT, and YSL contributed to the critical revision of the manuscript. All authors read and approved the final manuscript.</p></sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>This work was supported by grant from the Ministry of Science and Technology of the People&#x00027;s Republic of China (2018YFC1311303), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT310-01), the 2021 Youth Talent Promotion Project in Henan Province to KL (Grant No. 2021HYTP054), and 2021 Joint Construction Project of Henan Medical Science and Technology Breakthrough Plan to KL (Grant No. LHGJ20210336).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
</body>
<back>
<ack><p>We thank the study participants and the clinical staff for their support and contribution to this study.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>GBD</surname> <given-names>2019 Stroke Collaborators</given-names></name></person-group>. <article-title>Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Neurol.</source> (<year>2021</year>) <volume>20</volume>:<fpage>795</fpage>&#x02013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(21)00252-0</pub-id><pub-id pub-id-type="pmid">34487721</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baber</surname> <given-names>U</given-names></name> <name><surname>Mehran</surname> <given-names>R</given-names></name> <name><surname>Sartori</surname> <given-names>S</given-names></name> <name><surname>Schoos</surname> <given-names>MM</given-names></name> <name><surname>Sillesen</surname> <given-names>H</given-names></name> <name><surname>Muntendam</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the bioimage study</article-title>. <source>J Am Coll Cardiol.</source> (<year>2015</year>) <volume>65</volume>:<fpage>1065</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.01.017</pub-id><pub-id pub-id-type="pmid">25790876</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamtchum-Tatuene</surname> <given-names>J</given-names></name> <name><surname>Noubiap</surname> <given-names>JJ</given-names></name> <name><surname>Wilman</surname> <given-names>AH</given-names></name> <name><surname>Saqqur</surname> <given-names>M</given-names></name> <name><surname>Shuaib</surname> <given-names>A</given-names></name> <name><surname>Jickling</surname> <given-names>GC</given-names></name></person-group>. <article-title>Prevalence of high-risk plaques and risk of stroke in patients with asymptomatic carotid stenosis: a meta-analysis</article-title>. <source>JAMA Neurol.</source> (<year>2020</year>) <volume>77</volume>:<fpage>1524</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2658</pub-id><pub-id pub-id-type="pmid">32744595</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saba</surname> <given-names>L</given-names></name> <name><surname>Saam</surname> <given-names>T</given-names></name> <name><surname>J&#x000E4;ger</surname> <given-names>HR</given-names></name> <name><surname>Yuan</surname> <given-names>C</given-names></name> <name><surname>Hatsukami</surname> <given-names>TS</given-names></name> <name><surname>Saloner</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications</article-title>. <source>Lancet Neurol.</source> (<year>2019</year>) <volume>18</volume>:<fpage>559</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30035-3</pub-id><pub-id pub-id-type="pmid">30954372</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopczak</surname> <given-names>A</given-names></name> <name><surname>Schindler</surname> <given-names>A</given-names></name> <name><surname>Bayer-Karpinska</surname> <given-names>A</given-names></name> <name><surname>Koch</surname> <given-names>ML</given-names></name> <name><surname>Sepp</surname> <given-names>D</given-names></name> <name><surname>Zeller</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Complicated carotid artery plaques as a cause of cryptogenic stroke</article-title>. <source>J Am Coll Cardiol.</source> (<year>2020</year>) <volume>76</volume>:<fpage>2212</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2020.09.532</pub-id><pub-id pub-id-type="pmid">33153580</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krist</surname> <given-names>AH</given-names></name> <name><surname>Davidson</surname> <given-names>KW</given-names></name> <name><surname>Mangione</surname> <given-names>CM</given-names></name> <name><surname>Barry</surname> <given-names>MJ</given-names></name> <name><surname>Cabana</surname> <given-names>M</given-names></name> <name><surname>Caughey</surname> <given-names>AB</given-names></name> <etal/></person-group>. <article-title>Screening for asymptomatic carotid artery stenosis: us preventive services task force recommendation statement</article-title>. <source>JAMA.</source> (<year>2021</year>) <volume>325</volume>:<fpage>476</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.26988</pub-id><pub-id pub-id-type="pmid">33528542</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>L</given-names></name> <name><surname>Clarke</surname> <given-names>R</given-names></name> <name><surname>Bennett</surname> <given-names>D</given-names></name> <name><surname>Guo</surname> <given-names>Y</given-names></name> <name><surname>Walters</surname> <given-names>RG</given-names></name> <name><surname>Hill</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in chinese adults</article-title>. <source>Nat Med.</source> (<year>2019</year>) <volume>25</volume>:<fpage>569</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0366-x</pub-id><pub-id pub-id-type="pmid">30858617</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname> <given-names>MV</given-names></name> <name><surname>Millwood</surname> <given-names>IY</given-names></name> <name><surname>Kartsonaki</surname> <given-names>C</given-names></name> <name><surname>Hill</surname> <given-names>MR</given-names></name> <name><surname>Bennett</surname> <given-names>DA</given-names></name> <name><surname>Boxall</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke</article-title>. <source>J Am Coll Cardiol.</source> (<year>2018</year>) <volume>71</volume>:<fpage>620</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.006</pub-id><pub-id pub-id-type="pmid">29420958</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name> <name><surname>Sarwar</surname> <given-names>N</given-names></name> <name><surname>Perry</surname> <given-names>P</given-names></name> <name><surname>Kaptoge</surname> <given-names>S</given-names></name> <name><surname>Ray</surname> <given-names>KK</given-names></name> <name><surname>Thompson</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Major lipids, apolipoproteins, and risk of vascular disease</article-title>. <source>JAMA.</source> (<year>2009</year>) <volume>302</volume>:<fpage>1993</fpage>&#x02013;<lpage>2000</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2009.1619</pub-id><pub-id pub-id-type="pmid">19903920</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname> <given-names>SS</given-names></name> <name><surname>Hooper</surname> <given-names>AJ</given-names></name> <name><surname>Sullivan</surname> <given-names>DR</given-names></name> <name><surname>Burnett</surname> <given-names>JR</given-names></name></person-group>. <article-title>Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment</article-title>. <source>Pathology.</source> (<year>2019</year>) <volume>51</volume>:<fpage>148</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.pathol.2018.11.006</pub-id><pub-id pub-id-type="pmid">30595507</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>TA</given-names></name> <name><surname>Ito</surname> <given-names>MK</given-names></name> <name><surname>Maki</surname> <given-names>KC</given-names></name> <name><surname>Orringer</surname> <given-names>CE</given-names></name> <name><surname>Bays</surname> <given-names>HE</given-names></name> <name><surname>Jones</surname> <given-names>PH</given-names></name> <etal/></person-group>. <article-title>National lipid association recommendations for patient-centered management of dyslipidemia: part 1&#x02013;full report</article-title>. <source>J Clin Lipidol.</source> (<year>2015</year>) <volume>9</volume>:<fpage>129</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacl.2015.02.003</pub-id><pub-id pub-id-type="pmid">25911072</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Bartolo</surname> <given-names>BA</given-names></name> <name><surname>Cartland</surname> <given-names>SP</given-names></name> <name><surname>Genner</surname> <given-names>S</given-names></name> <name><surname>Manuneedhi Cholan</surname> <given-names>P</given-names></name> <name><surname>Vellozzi</surname> <given-names>M</given-names></name> <name><surname>Rye</surname> <given-names>KA</given-names></name> <etal/></person-group>. <article-title>HDL improves cholesterol and glucose homeostasis and reduces atherosclerosis in diabetes-associated atherosclerosis</article-title>. <source>J Diabetes Res.</source> (<year>2021</year>) <volume>2021</volume>:<fpage>6668506</fpage>. <pub-id pub-id-type="doi">10.1155/2021/6668506</pub-id><pub-id pub-id-type="pmid">34095317</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname> <given-names>SM</given-names></name> <name><surname>Stone</surname> <given-names>NJ</given-names></name> <name><surname>Bailey</surname> <given-names>AL</given-names></name> <name><surname>Beam</surname> <given-names>C</given-names></name> <name><surname>Birtcher</surname> <given-names>KK</given-names></name> <name><surname>Blumenthal</surname> <given-names>RS</given-names></name> <etal/></person-group>. <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source>Circulation.</source> (<year>2019</year>) <volume>139</volume>:<fpage>e1082</fpage>&#x02013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000698</pub-id><pub-id pub-id-type="pmid">31206330</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badim&#x000F3;n</surname> <given-names>JJ</given-names></name> <name><surname>Santos-Gallego</surname> <given-names>CG</given-names></name> <name><surname>Badim&#x000F3;n</surname> <given-names>L</given-names></name></person-group>. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. <source>Revista espanola de cardiologia.</source> (<year>2010</year>) <volume>63</volume>(<supplement>Suppl 2</supplement>):<fpage>20</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0300-8932(10)70150-0</pub-id><pub-id pub-id-type="pmid">20540898</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>N</given-names></name> <name><surname>Hu</surname> <given-names>X</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name> <name><surname>Bai</surname> <given-names>P</given-names></name> <name><surname>Cai</surname> <given-names>M</given-names></name> <name><surname>Zeng</surname> <given-names>TS</given-names></name> <etal/></person-group>. <article-title>Non-high-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratio is an independent risk factor for diabetes mellitus: results from a population-based cohort study</article-title>. <source>J Diabetes.</source> (<year>2018</year>) <volume>10</volume>:<fpage>708</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1111/1753-0407.12650</pub-id><pub-id pub-id-type="pmid">29437292</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>D</given-names></name> <name><surname>Qi</surname> <given-names>Y</given-names></name> <name><surname>Huang</surname> <given-names>C</given-names></name> <name><surname>Wu</surname> <given-names>M</given-names></name> <name><surname>Wang</surname> <given-names>C</given-names></name> <name><surname>Li</surname> <given-names>F</given-names></name> <etal/></person-group>. <article-title>Associations of lipid parameters with insulin resistance and diabetes: a population-based study</article-title>. <source>Clin Nutr.</source> (<year>2018</year>) <volume>37</volume>:<fpage>1423</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.clnu.2017.06.018</pub-id><pub-id pub-id-type="pmid">28673690</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>T</given-names></name> <name><surname>Yuan</surname> <given-names>G</given-names></name> <name><surname>Zhang</surname> <given-names>M</given-names></name> <name><surname>Zhou</surname> <given-names>X</given-names></name> <name><surname>Sun</surname> <given-names>X</given-names></name> <name><surname>Yu</surname> <given-names>X</given-names></name></person-group>. <article-title>Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance</article-title>. <source>Cardiovasc Diabetol.</source> (<year>2014</year>) <volume>13</volume>:<fpage>146</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-014-0146-3</pub-id><pub-id pub-id-type="pmid">25326814</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>S</given-names></name> <name><surname>Zhong</surname> <given-names>J</given-names></name> <name><surname>Ye</surname> <given-names>M</given-names></name> <name><surname>Miao</surname> <given-names>L</given-names></name> <name><surname>Lu</surname> <given-names>G</given-names></name> <name><surname>Xu</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in chinese children and adolescents: a large single-center cross-sectional study</article-title>. <source>Lipids Health Dis.</source> (<year>2020</year>) <volume>19</volume>:<fpage>242</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-020-01421-5</pub-id><pub-id pub-id-type="pmid">33222696</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>K</given-names></name> <name><surname>Shan</surname> <given-names>S</given-names></name> <name><surname>Zheng</surname> <given-names>H</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name> <name><surname>Chen</surname> <given-names>C</given-names></name> <name><surname>Liu</surname> <given-names>C</given-names></name></person-group>. <article-title>Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study</article-title>. <source>Lipids Health Dis.</source> (<year>2018</year>) <volume>17</volume>:<fpage>196</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-018-0848-8</pub-id><pub-id pub-id-type="pmid">30131058</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>SW</given-names></name> <name><surname>Jee</surname> <given-names>JH</given-names></name> <name><surname>Kim</surname> <given-names>HJ</given-names></name> <name><surname>Jin</surname> <given-names>SM</given-names></name> <name><surname>Suh</surname> <given-names>S</given-names></name> <name><surname>Bae</surname> <given-names>JC</given-names></name> <etal/></person-group>. <article-title>Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1</article-title>. <source>Int J Cardiol.</source> (<year>2013</year>) <volume>168</volume>:<fpage>2678</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2013.03.027</pub-id><pub-id pub-id-type="pmid">23545148</pub-id></citation></ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname> <given-names>G</given-names></name> <name><surname>Tu</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>C</given-names></name> <name><surname>Tang</surname> <given-names>X</given-names></name> <name><surname>Luo</surname> <given-names>L</given-names></name> <name><surname>Wu</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>The value of the apoB/apoA? ratio and the non-HDL-C/HDL-C ratio in predicting carotid atherosclerosis among chinese individuals with metabolic syndrome: a cross-sectional study</article-title>. <source>Lipids Health Dis.</source> (<year>2015</year>) <volume>14</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-015-0023-4</pub-id><pub-id pub-id-type="pmid">25885111</pub-id></citation></ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname> <given-names>W</given-names></name> <name><surname>Epstein</surname> <given-names>T</given-names></name> <name><surname>Huer&#x000ED;n</surname> <given-names>M</given-names></name> <name><surname>Lobo</surname> <given-names>M</given-names></name> <name><surname>Molinero</surname> <given-names>G</given-names></name> <name><surname>Siniawski</surname> <given-names>D</given-names></name></person-group>. <article-title>Association between non-HDL-C/HDL-C ratio and carotid atherosclerosis in postmenopausal middle-aged women</article-title>. <source>Climacteric.</source> (<year>2019</year>) <volume>22</volume>:<fpage>518</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1080/13697137.2019.1631787</pub-id><pub-id pub-id-type="pmid">31287342</pub-id></citation></ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>Z</given-names></name> <name><surname>Xia</surname> <given-names>B</given-names></name> <name><surname>Wang</surname> <given-names>L</given-names></name> <name><surname>Zhang</surname> <given-names>H</given-names></name> <name><surname>Zhu</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Relationship between the non-HDLC-to-HDLC ratio and carotid plaques in a high stroke risk population: a cross-sectional study in China</article-title>. <source>Lipids Health Dis.</source> (<year>2020</year>) <volume>19</volume>:<fpage>168</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-020-01344-1</pub-id><pub-id pub-id-type="pmid">32660519</pub-id></citation></ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virani</surname> <given-names>SS</given-names></name> <name><surname>Catellier</surname> <given-names>DJ</given-names></name> <name><surname>Pompeii</surname> <given-names>LA</given-names></name> <name><surname>Nambi</surname> <given-names>V</given-names></name> <name><surname>Hoogeveen</surname> <given-names>RC</given-names></name> <name><surname>Wasserman</surname> <given-names>BA</given-names></name> <etal/></person-group>. <article-title>Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the atherosclerosis risk in communities (ARIC) carotid MRI Study</article-title>. <source>Atherosclerosis.</source> (<year>2011</year>) <volume>219</volume>:<fpage>596</fpage>&#x02013;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.08.001</pub-id><pub-id pub-id-type="pmid">21868017</pub-id></citation></ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nidorf</surname> <given-names>SM</given-names></name> <name><surname>Fiolet</surname> <given-names>A</given-names></name> <name><surname>Abela</surname> <given-names>GS</given-names></name></person-group>. <article-title>Viewing atherosclerosis through a crystal lens: how the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability</article-title>. <source>J Clin Lipidol.</source> (<year>2020</year>) <volume>14</volume>:<fpage>619</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacl.2020.07.003</pub-id><pub-id pub-id-type="pmid">32792218</pub-id></citation></ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>L</given-names></name> <name><surname>Lu</surname> <given-names>Z</given-names></name> <name><surname>Zhu</surname> <given-names>L</given-names></name> <name><surname>Ouyang</surname> <given-names>X</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name> <name><surname>He</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people</article-title>. <source>Kardiologia Polska.</source> (<year>2015</year>) <volume>73</volume>:<fpage>931</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5603/KP.a2015.0086</pub-id><pub-id pub-id-type="pmid">25985729</pub-id></citation></ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouvari</surname> <given-names>M</given-names></name> <name><surname>Panagiotakos</surname> <given-names>DB</given-names></name> <name><surname>Chrysohoou</surname> <given-names>C</given-names></name> <name><surname>Georgousopoulou</surname> <given-names>EN</given-names></name> <name><surname>Tousoulis</surname> <given-names>D</given-names></name> <name><surname>Pitsavos</surname> <given-names>AC</given-names></name></person-group>. <article-title>Sex-related differences of the effect of lipoproteins and apolipoproteins on 10-year cardiovascular disease risk; insights from the Attica Study (2002-2012)</article-title>. <source>Molecules.</source> (<year>2020</year>) <volume>25</volume>:<fpage>1506</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25071506</pub-id><pub-id pub-id-type="pmid">32225033</pub-id></citation></ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="book"><person-group person-group-type="author"><name><surname>Touboul</surname> <given-names>PJ</given-names></name> <name><surname>Hennerici</surname> <given-names>MG</given-names></name> <name><surname>Meairs</surname> <given-names>S</given-names></name> <name><surname>Adams</surname> <given-names>H</given-names></name> <name><surname>Amarenco</surname> <given-names>P</given-names></name> <name><surname>Bornstein</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011)</article-title>. In: <source>An Update on Behalf of the Advisory Board of the 3rd, 4th and 5th Watching the Risk Symposia, at the 13th, 15th and 20th European Stroke Conferences.</source> <publisher-loc>Mannheim; Brussels</publisher-loc>; <publisher-name>Hamburg</publisher-name> (<year>2012</year>). p. <fpage>290</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1159/000343145</pub-id><pub-id pub-id-type="pmid">23128470</pub-id></citation></ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Touboul</surname> <given-names>PJ</given-names></name> <name><surname>Hennerici</surname> <given-names>MG</given-names></name> <name><surname>Meairs</surname> <given-names>S</given-names></name> <name><surname>Adams</surname> <given-names>H</given-names></name> <name><surname>Amarenco</surname> <given-names>P</given-names></name> <name><surname>Desvarieux</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Mannheim intima-media thickness consensus</article-title>. <source>Cerebrovasc Dis.</source> (<year>2004</year>) <volume>18</volume>:<fpage>346</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000081812</pub-id><pub-id pub-id-type="pmid">15523176</pub-id></citation></ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sztajzel</surname> <given-names>R</given-names></name></person-group>. <article-title>Ultrasonographic assessment of the morphological characteristics of the carotid plaque</article-title>. <source>Swiss Med Weekly.</source> (<year>2005</year>) <volume>135</volume>:<fpage>635</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">16380850</pub-id></citation></ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poredo&#x00161;</surname> <given-names>P</given-names></name> <name><surname>Cevc</surname> <given-names>M</given-names></name> <name><surname>Blinc</surname> <given-names>A</given-names></name></person-group>. <article-title>Characteristics of atherosclerosis in femoropopliteal artery and its clinical relevance</article-title>. <source>Atherosclerosis.</source> (<year>2021</year>) <volume>335</volume>:<fpage>31</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2021.09.012</pub-id><pub-id pub-id-type="pmid">34547588</pub-id></citation></ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>P</given-names></name> <name><surname>Fang</surname> <given-names>Z</given-names></name> <name><surname>Wang</surname> <given-names>H</given-names></name> <name><surname>Cai</surname> <given-names>Y</given-names></name> <name><surname>Rahimi</surname> <given-names>K</given-names></name> <name><surname>Zhu</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study</article-title>. <source>Lancet Global Health.</source> (<year>2020</year>) <volume>8</volume>:<fpage>e721</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(20)30117-0</pub-id><pub-id pub-id-type="pmid">32353319</pub-id></citation></ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname> <given-names>YC</given-names></name> <name><surname>Gonzalez</surname> <given-names>NR</given-names></name></person-group>. <article-title>Management of extracranial carotid artery disease</article-title>. <source>Cardiol Clin.</source> (<year>2015</year>) <volume>33</volume>:<fpage>1</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccl.2014.09.001</pub-id><pub-id pub-id-type="pmid">25439328</pub-id></citation></ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname> <given-names>AR</given-names></name> <name><surname>Ricco</surname> <given-names>JB</given-names></name> <name><surname>de Borst</surname> <given-names>GJ</given-names></name> <name><surname>Debus</surname> <given-names>S</given-names></name> <name><surname>de Haro</surname> <given-names>J</given-names></name> <name><surname>Halliday</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Editor&#x00027;s choice - management of atherosclerotic carotid and vertebral artery disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)</article-title>. <source>Eur J Vasc Endovasc Surg.</source> (<year>2018</year>) <volume>55</volume>:<fpage>3</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejvs.2017.10.014</pub-id><pub-id pub-id-type="pmid">29673812</pub-id></citation></ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saba</surname> <given-names>L</given-names></name> <name><surname>Brinjikji</surname> <given-names>W</given-names></name> <name><surname>Spence</surname> <given-names>JD</given-names></name> <name><surname>Wintermark</surname> <given-names>M</given-names></name> <name><surname>Castillo</surname> <given-names>M</given-names></name> <name><surname>Borst</surname> <given-names>GJD</given-names></name> <etal/></person-group>. <article-title>Roadmap consensus on carotid artery plaque imaging and impact on therapy strategies and guidelines: an international, multispecialty, expert review and position statement</article-title>. <source>Am J Neuroradiol.</source> (<year>2021</year>) <volume>42</volume>:<fpage>1566</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.3174/ajnr.A7223</pub-id><pub-id pub-id-type="pmid">34326105</pub-id></citation></ref>
<ref id="B36">
<label>36.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willeit</surname> <given-names>P</given-names></name> <name><surname>Tschiderer</surname> <given-names>L</given-names></name> <name><surname>Allara</surname> <given-names>E</given-names></name> <name><surname>Reuber</surname> <given-names>K</given-names></name> <name><surname>Seekircher</surname> <given-names>L</given-names></name> <name><surname>Gao</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients</article-title>. <source>Circulation.</source> (<year>2020</year>) <volume>142</volume>:<fpage>621</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046361</pub-id><pub-id pub-id-type="pmid">32546049</pub-id></citation></ref>
<ref id="B37">
<label>37.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>A</given-names></name> <name><surname>Chen</surname> <given-names>S</given-names></name> <name><surname>Wu</surname> <given-names>S</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name></person-group>. <article-title>Association between non-high-density lipoprotein cholesterol levels and asymptomatic vulnerable carotid atherosclerotic plaques</article-title>. <source>Eur J Neurol.</source> (<year>2019</year>) <volume>26</volume>:<fpage>1433</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/ene.13973</pub-id><pub-id pub-id-type="pmid">31002203</pub-id></citation></ref>
<ref id="B38">
<label>38.</label>
<citation citation-type="journal"><person-group person-group-type="author"><collab>Expert Expert Panel on Detection Evaluation and and Treatment of High Blood Cholesterol in Adults</collab></person-group>. <article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III)</article-title>. <source>JAMA.</source> (<year>2001</year>) <volume>285</volume>:<fpage>2486</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1001/jama.285.19.2486</pub-id><pub-id pub-id-type="pmid">11368702</pub-id></citation></ref>
<ref id="B39">
<label>39.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname> <given-names>F</given-names></name> <name><surname>Baigent</surname> <given-names>C</given-names></name> <name><surname>Catapano</surname> <given-names>AL</given-names></name> <name><surname>Koskinas</surname> <given-names>KC</given-names></name> <name><surname>Casula</surname> <given-names>M</given-names></name> <name><surname>Badimon</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk</article-title>. <source>Atherosclerosis.</source> (<year>2019</year>) <volume>290</volume>:<fpage>140</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehz455</pub-id><pub-id pub-id-type="pmid">31591002</pub-id></citation></ref>
<ref id="B40">
<label>40.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos-Gallego</surname> <given-names>CG</given-names></name> <name><surname>Rosenson</surname> <given-names>RS</given-names></name></person-group>. <article-title>Role of HDL in those with diabetes</article-title>. <source>Curr Cardiol Rep.</source> (<year>2014</year>) <volume>16</volume>:<fpage>512</fpage>. <pub-id pub-id-type="doi">10.1007/s11886-014-0512-5</pub-id><pub-id pub-id-type="pmid">24950673</pub-id></citation></ref>
<ref id="B41">
<label>41.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos-Gallego</surname> <given-names>CG</given-names></name> <name><surname>Giannarelli</surname> <given-names>C</given-names></name> <name><surname>Badim&#x000F3;n</surname> <given-names>JJ</given-names></name></person-group>. <article-title>Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux</article-title>. <source>Curr Atheroscler Rep.</source> (<year>2011</year>) <volume>13</volume>:<fpage>266</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1007/s11883-011-0177-0</pub-id><pub-id pub-id-type="pmid">21484293</pub-id></citation></ref>
</ref-list> 
</back>
</article> 